about
Cellectis SA is a clinical stage biotechnological company, employing the core proprietary technologies to develop products based on gene-editing, with a portfolio of allogeneic Chimeric Antigen Receptor T-cells, or UCART, product candidates in the fi...
Read More
3.98
-0.54
(-11.95%)
218.7K
XNAS Volume
XNAS 17 Oct, 2025 5:30 PM (EDT)
Low Financial Strength
Expensive Valuation
Technically Bullish
Momentum Trap
These stocks are with a bad quality and poor financial score ranging from medium to expensive valuation. Rising technical aspects may attract investors, but, weak financials cannot be overlooked.
View Similar
Embed DVM
Cellectis ADR Live Price Chart
Switch to TradingView
Loading Fundamental data..
Loading data..